RIGL

Rigel Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03

Figures on this page computed 2026-11-08 12:56 UTC

Last close

51.29USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-03

1.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-08-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Follow one dollar

lens 1 of 9

After what it costs to make

93.3%

After running the business

42.6%

After interest and tax

125%

After what it must reinvest

n/a

Kept after the dividend

n/a

after what it costs to make, 93.3% of sales; after running the business, 42.6% of sales; after interest and tax, 124.7% of sales

The five stops

3 of 5 read

After what it costs to make274,661,00093.3%
After running the business125,466,00042.6%
After interest and tax367,024,000125%
After what it must reinvestn/an/a
Kept after the dividendn/an/a

The last stop is empty on purpose. This filing does not tag a common dividend, so what is kept after it cannot be worked out. That is not the same fact as a company that paid no dividend, and we will not print a zero for it.

What is left after the dividend is not held for this company.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-03

Sales294,282,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
After what it costs to make274,661,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
After running the business125,466,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
After interest and tax367,024,000
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
After what it must reinvestn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself
Kept after the dividendn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001034842-26-000015
Reported in
USD
The filing itself